secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protagenic Therapeutics, Inc.new (PTIX)
CIK:        0001022899
Form:       8-K
Filed at:   2022-11-29T23:59:59+00:00
Accession:  0001493152-22-033864
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.07, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Shareholders approve reverse split; company updates PT00114 trial timeline
--------------------------------------------------------------------------

- Stockholders approved a reverse stock split of 1:2 to 1:4, with board discretion on exact ratio.
- Elected Khalil Barrage and Timothy R. Wright as Class I directors until 2025.
- PT00114: U.S. IND submission expected by end of 2022; German ethics committee approved, awaiting BfArM.
- Company anticipates Phase I start in Q1 2023 and first human safety readouts within 12 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1022899/000149315222033864/0001493152-22-033864-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1022899/000149315222033864/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-033864

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer